Sarepta Therapeutics (NASDAQ:SRPT), a developer of innovative
RNA-targeted therapeutics, today announced that management will be
presenting a company overview and update at the 2015 Morgan Stanley
Global Healthcare Conference in New York, NY. Edward Kaye, Sarepta’s
interim chief executive officer and chief medical officer, will
represent the company in a fireside chat on Thursday, September
17 at 4:40 PM Eastern Time.
The fireside chat will be webcast live on the investor relations section
of the Sarepta Therapeutics website at www.sarepta.com and
will be archived under the Events and Presentations section
following the presentation for 90 days. Please connect to Sarepta’s
website several minutes prior to the start of the broadcast to ensure
adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company focused on the
discovery and development of unique RNA-targeted therapeutics for the
treatment of rare, infectious and other diseases. The Company is
primarily focused on rapidly advancing the development of its
potentially disease-modifying DMD drug candidates, including its lead
DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is
also developing therapeutics for the treatment of infectious diseases,
such as drug-resistant bacteria and other rare human diseases. For more
information, please visit us at www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in
the 'For Investors' section of our website at www.sarepta.com.
We encourage investors and potential investors to consult our website
regularly for important information about us.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150910005564/en/
Copyright Business Wire 2015